Adina Ballaban

Feb 3, 2023 | jacionline.org | Julie M. Caldwell |Adina Ballaban |Jie Li |Bristol Myers Squibb

The molecular pathogenesis of the type 2 inflammatory disease eosinophilic esophagitis (EoE) is largely driven by IL-13-mediated effects. A humanized monoclonal anti-IL-13 antibody (cendakimab) lowered esophageal eosinophils and improved outcomes in clinical trials. We aimed to determine how systemic cendakimab administration impacted local esophageal gene expression in a substudy of a double-blind, placebo-controlled phase 2 trial (NCT02098473).